Mineralys announces new subgroup analyses from Phase 3 Launch-HTN trial

Mineralys Therapeutics (MLYS) announced new subgroup analyses from the Phase 3 Launch-HTN trial, evaluating the blood pressure-lowering efficacy and safety of lorundrostat in difficult-to-treat and high-risk patient populations with high unmet medical need. The results were presented at the American Heart Association, AHA, Hypertension Scientific Sessions in Baltimore, MD, September 4-7, 2025. Launch-HTN is the largest global Phase 3 trial to date in uncontrolled or resistant hypertension. Across all of these subgroups, lorundrostat 50 mg demonstrated consistent, statistically significant, and clinically meaningful reductions in blood pressure compared with placebo. Safety and tolerability outcomes were favorable across all groups in the trial, with results consistent with the overall study population. No new safety signals were observed, and adverse events were generally mild or moderate in severity.